ClinicalTrials.gg
Active, not recruitingNCT05196035FIONAUpdated Oct 15, 2026

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

A Phase 3 interventional study of Finerenone (Kerendia, BAY94-8862) and Placebo in Chronic Kidney Disease and Proteinuria, sponsored by Bayer. Active, not recruiting at 132 sites in 32 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Updated Oct 15, 202618 sites added18 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
6 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing finerenone in Renal Insufficiency, Chronic — 14 open to participants now, 16 under way, 4 of them phase 3. finerenone · Renal Insufficiency, Chronic.

Planned enrollment
7th of 25
219 · median 100
Started
2022
with 2 others
Phase 3
6 of 25
3 open now
Primary completion
2027-04
later than 6 of 15 live
Registered
4th of 25
by date
Lead sponsor
8 of 25
Bayer

Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, this one is the 7th largest by planned enrollment, is one of 3 that started in 2022, is one of 6 in phase 3, reaches primary completion later than 6 of the 15 other live ones, and was the 4th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

14 of the 25 studies testing finerenone in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 6 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing finerenone in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine.

The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and/or proteinuria. These include "angiotensin-converting enzyme inhibitors" (ACEI) and "angiotensin receptor blockers" (ARB). Both ACEI and ARB can improve kidney function by helping the renin-angiotensin-aldosterone system (RAAS) to work normally. The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can stop the kidneys from working properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system.

The study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB.

So, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function.

The main purpose of this study is to learn more about whether finerenone added to either ACEI or ARB can help reduce the amount of protein in the participants' urine more than a placebo. A placebo looks like a treatment but does not have any medicine in it. Participants will also continue to receive their other medications.

To see how the treatment work, the doctors will take samples of the participants' urine to measure their protein levels before and during taking treatment and after their last treatment. In addition, blood samples will be taken to monitor kidney function, electrolytes and the amount of finerenone in the blood as well as for other tests.

This study will include children with CKD and proteinuria aged from 6 months up to less than 18 years. The participants will take:

  • either finerenone or the placebo, in addition to
  • either ACEI or ARB, whichever they take as part of their normal treatment

Two visits are required up to 104 days, to check whether a child can take part in the treatment phase of the study. If participants qualify for the treatment phase, they will then undergo treatment for about 180 days. During this time, they will visit the study site at least 7 times. During these visits, the participants will:

  • have their blood pressure, heart rate, temperature, height and weight measured
  • have blood and urine samples taken
  • have physical examinations
  • have their heart examined by an electrocardiogram and echocardiography (a sonogram of the heart)
  • answer questions about their medication and whether they have any adverse events , or have their parents or guardians answer
  • answer questions about how they are feeling, or have their parents or guardians answer
  • answer question about how they like the study medication, or have their parents or guardians answer

The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

The doctors will check the participants' health about 30 days after the participants take their last treatment.

03

Conditions studied

  • Chronic Kidney Disease
  • Proteinuria
04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 6 months to \<18 years old at the time when the /assent is signed
  • Participants must have a clinical diagnosis of chronic kidney disease (CKD) at screening which is defined as

    • CKD stages 1-3 ( ≥30 mL/min/1.73m\^2) for children ≥1 year to \<18 years of age or
    • a serum creatinine ≤ 0.40 mg/dL for infants 6 months to \< 1 year of age and
    • severely increased proteinuria as defined by

      • Urinary protein-to-creatinine ratio (UPCR) of ≥ 0.50 g/g in participants ≥ 2 years with CKD stage 2 and 3 or
      • UPCR ≥ 1.0 g/g for patients \< 2 years of age or ≥ 2 years of age and with CKD stage 1
  • Participants must have stable kidney function between screening and D0 defined as:

    • For participants with a creatinine of > 0.8 mg/dL at screening: no increase or decrease in eGFR by ≥ 20% at D0
    • For participants with a creatinine of ≤ 0.8 mg/dL at screening: no increase or decrease in creatinine ≥ 0.15 mg/dL at D0.
  • Treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at optimized doses defined as maximally tolerable doses within the recommended dose range according to guidelines on blood pressure management, unchanged for at least 30 days prior to screening
  • K+ ≤5.0 mmol/L for children ≥2 years of age at both screening and D0, and ≤5.3 mmol/L for children \<2 years of age at both screening and D0

Exclusion criteria

Exclusion Criteria:

  • Planned urological surgery expected to influence renal function
  • Children with hemolytic uremic syndrome (HUS) diagnosed ≤6 months prior to screening
  • Patients with nephrotic syndrome receiving albumin infusions within the last 6 months prior to screening
  • Patients who are candidates for renal transplantation, i.e., a kidney transplantation scheduled within the study time frame
  • Renal allograft in place
  • Bilateral renal artery stenosis
  • Acute kidney injury requiring dialysis within 6 months prior to screening
  • Systemic hypertension stage 2 in children ≥1 year of age defined according to guidelines on blood pressure management at screening or randomization
  • Systolic blood pressure (SBP) above 110 mmHg in infants 6 months to \<1 year of age at screening or randomization
  • Systemic hypotension defined as a systolic blood pressure below the 5th percentile for age, sex and height at either screening or randomization but no lower than 80 mmHg (although for some participants the 5th percentile of SBP is \< 80 mmHg they must be excluded if their SBP is \<80 mmHg)
  • Participants with immune-mediated CKD using rituximab, cyclophosphamide, abatacept, or high-dose , within \<6 months prior to screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
219 participants (estimated)

Study arms

  • Experimental
    Finerenone (Kerendia, BAY94-8862)

    Participants will receive finerenone treatment.

    Drug: Finerenone (Kerendia, BAY94-8862)

  • Placebo comparator
    Placebo

    Participants will receive placebo to finerenone.

    Drug: Placebo

Interventions

  • Finerenone in different doses, treatment duration will be 180±7 days

  • DrugPlacebo

    Placebo to finerenone, treatment duration will be 180±7 days

06

What researchers measure

Primary outcomes

  1. Percent change in Urinary protein-to-creatinine ratio (UPCR) reduction from baseline to day 180+/-7

    Percent change from baseline to day 180±7 in UPCR will be calculated.

    Time frame: From baseline to day 180+/-7

Secondary outcomes

  1. Number participants with treatment emergent adverse events (TEAEs)

    Below sub-categories will be considered: 1. Serious Treatment Emergent Adverse Events (TEAEs) 2. TEAEs and serious TEAEs leading to discontinuation of treatment 3. Study drug related TEAEs and serious TEAEs 4. TEAEs categorized by severity (mild, moderate, severe) 5. TEAEs by maximum intensity 6. Number of participants hospitalized with hyperkalemia, 7. Number of participants discontinuing due to hyperkalemia, 8. Number of participants with hospitalization for worsening of renal function 9. Number of participants discontinuing due to worsening of renal function

    Time frame: From the start of study intervention to last study intervention + 3 days (up to 190 days)

  2. Change in serum potassium levels from baseline to day 180±7

    Time frame: From baseline to day 180±7

  3. Change in serum creatinine from baseline to day 180±7

    Time frame: From baseline to day 180±7

  4. Change in eGFR from baseline to day 180±7

    Estimated glomerular filtration rate (eGFR)

    Time frame: From baseline to day 180±7

  5. Change in systolic blood pressure from baseline to day 180±7

    Time frame: From baseline to day 180±7

  6. UPCR reduction of at least 30% from baseline to day 180+/-7

    Proportion of participants at day 180+/-7 with a \>=30% reduction in PUCR compared to baseline

    Time frame: From baseline to day 180±7

  7. Change in UACR from baseline to day 180±7

    Urinary albumin-to-creatinine ratio (UACR)

    Time frame: From baseline to day 180±7

  8. Pharmacokinetics (PK) finerenone Cmax, md

    Maximum observed finerenone concentration in plasma after multiple doses.

    Time frame: Pre-dose, post-dose (1.5-5 hours after intake of intervention), up to day 180±7

  9. Pharmacokinetics (PK) finerenone AUCτ,md

    Area under the curve for finerenone concentration in plasma after multiple doses.

    Time frame: Pre-dose, post-dose (1.5-5 hours after intake of intervention), up to day 180±7

  10. Taste and texture questionnaire of the pediatric formulation

    Time frame: On day 30±3 and day 180±7

07

Study locations

132 sites

Showing the first 100 of 132 sites across 32 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Schaefer F, Montini G, Kang HG, Walle JV, Zaritsky J, Schreuder MF, Litwin M, Scalise A, Scott H, Potts J, Iveli P, Breitenstein S, Warady BA. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies. Trials. 2024 Mar 21;25(1):203. doi: 10.1186/s13063-024-08021-z. PubMed 38509517 ↗

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Apr 2027, 60 months after the start.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's planned 60 months is above that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2022
First posted
Jan 19, 2022
StartActual
Mar 28, 2022
Primary completionEst.
Apr 10, 2027
CompletionEst.
May 10, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites added, 18 sites removed
Show 18 added (6 Italy, 4 Poland, 3 France, 3 Israel, 1 Spain, 1 Turkey (Türkiye))
  • CHU Lyon - Hopital Femme Mere Enfant - Service de nephrologie-rhumatologie-dermatologie pediatriques · Bron, France
  • CHU Strasbourg - Hopital Hautepierre - Service nephrologie pediatrique · Strasbourg, France
  • CHU Montpellier - Hopital Arnaud de Villeneuve - Service nephrologie pediatrique · Montpellier, France
  • Clalit Health Services Schneider Children's Medical Center · Petah Tikva, Israel
  • Health Corporation of Galilee Medical Center · Nahariya, Israel
  • Clalit Health | Soroka Medical Center · Beersheba, Israel
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Pediatria · Bologna, Italy
  • Ospedale Pediatrico Bambino Gesù - Nefrologia · Rome, Italy
  • IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene · Genoa, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Nefrologia e Dialisi Pediatrica, Trapianti di Rene · Milan, Italy
  • A.O.U. Città della Salute e della Scienza di Torino_Regina Margherita - Nefrologia Pediatrica · Turin, Italy
  • Azienda Ospedaliera Universitaria Meyer IRCCS - Nefrologia e Dialisi · Florence, Italy
  • Instytut "Pomnik - Centrum Zdrowia Dziecka" · Warsaw, Poland
  • Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa · Bialystok, Poland
  • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
  • Instytut Centrum Zdrowia Matki Polki · Lodz, Poland
  • Hospital Universitari Vall D Hebron | Nefrologia pediatrica · Barcelona, Spain
  • T.C. Saglik Bakanligi Ankara Bilkent Sehir Hastanesi Noroloji ve Ortopedi Hastanesi Noroloji Bolumu · Ankara, Turkey (Türkiye)
Show 18 removed
  • CHU Lyon - Hopital Femme Mere Enfant - Service de nephrologie-rhumatologie-dermatologie pediatriques · Bron, France
  • CHU Montpellier - Hopital Arnaud de Villeneuve - Service nephrologie pediatrique · Montpellier, France
  • CHU Strasbourg - Hopital Hautepierre - Service nephrologie pediatrique · Strasbourg, France
  • Clalit Health | Soroka Medical Center · Beersheba, Israel
  • Health Corporation of Galilee Medical Center · Nahariya, Israel
  • Clalit Health Services Schneider Children's Medical Center · Petah Tikva, Israel
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Pediatria · Bologna, Italy
  • Azienda Ospedaliera Universitaria Meyer IRCCS - Nefrologia e Dialisi · Florence, Italy
  • IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene · Genova, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Nefrologia e Dialisi Pediatrica, Trapianti di Rene · Milan, Italy
  • Ospedale Pediatrico Bambino Gesù - Nefrologia · Roma, Italy
  • A.O.U. Città della Salute e della Scienza di Torino_Regina Margherita - Nefrologia Pediatrica · Torino, Italy
  • Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa · Bialystok, Poland
  • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
  • Instytut Centrum Zdrowia Matki Polki · Lodz, Poland
  • Instytut "Pomnik - Centrum Zdrowia Dziecka" · Warsaw, Poland
  • Hospital Universitari Vall D Hebron | Nefrologia pediatrica · Barcelona, Spain
  • T.C. Saglik Bakanligi Ankara Bilkent Sehir Hastanesi Noroloji ve Ortopedi Hastanesi Noroloji Bolumu · Ankara, Turkey (Türkiye)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    18 sites added, 18 sites removed
    Show 18 added (6 Italy, 4 Poland, 3 France, 3 Israel, 1 Spain, 1 Turkey (Türkiye))
    • CHU Lyon - Hopital Femme Mere Enfant - Service de nephrologie-rhumatologie-dermatologie pediatriques · Bron, France
    • CHU Strasbourg - Hopital Hautepierre - Service nephrologie pediatrique · Strasbourg, France
    • CHU Montpellier - Hopital Arnaud de Villeneuve - Service nephrologie pediatrique · Montpellier, France
    • Clalit Health Services Schneider Children's Medical Center · Petah Tikva, Israel
    • Health Corporation of Galilee Medical Center · Nahariya, Israel
    • Clalit Health | Soroka Medical Center · Beersheba, Israel
    • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Pediatria · Bologna, Italy
    • Ospedale Pediatrico Bambino Gesù - Nefrologia · Rome, Italy
    • IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene · Genoa, Italy
    • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Nefrologia e Dialisi Pediatrica, Trapianti di Rene · Milan, Italy
    • A.O.U. Città della Salute e della Scienza di Torino_Regina Margherita - Nefrologia Pediatrica · Turin, Italy
    • Azienda Ospedaliera Universitaria Meyer IRCCS - Nefrologia e Dialisi · Florence, Italy
    • Instytut "Pomnik - Centrum Zdrowia Dziecka" · Warsaw, Poland
    • Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa · Bialystok, Poland
    • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
    • Instytut Centrum Zdrowia Matki Polki · Lodz, Poland
    • Hospital Universitari Vall D Hebron | Nefrologia pediatrica · Barcelona, Spain
    • T.C. Saglik Bakanligi Ankara Bilkent Sehir Hastanesi Noroloji ve Ortopedi Hastanesi Noroloji Bolumu · Ankara, Turkey (Türkiye)
    Show 18 removed
    • CHU Lyon - Hopital Femme Mere Enfant - Service de nephrologie-rhumatologie-dermatologie pediatriques · Bron, France
    • CHU Montpellier - Hopital Arnaud de Villeneuve - Service nephrologie pediatrique · Montpellier, France
    • CHU Strasbourg - Hopital Hautepierre - Service nephrologie pediatrique · Strasbourg, France
    • Clalit Health | Soroka Medical Center · Beersheba, Israel
    • Health Corporation of Galilee Medical Center · Nahariya, Israel
    • Clalit Health Services Schneider Children's Medical Center · Petah Tikva, Israel
    • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Pediatria · Bologna, Italy
    • Azienda Ospedaliera Universitaria Meyer IRCCS - Nefrologia e Dialisi · Florence, Italy
    • IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene · Genova, Italy
    • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Nefrologia e Dialisi Pediatrica, Trapianti di Rene · Milan, Italy
    • Ospedale Pediatrico Bambino Gesù - Nefrologia · Roma, Italy
    • A.O.U. Città della Salute e della Scienza di Torino_Regina Margherita - Nefrologia Pediatrica · Torino, Italy
    • Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa · Bialystok, Poland
    • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
    • Instytut Centrum Zdrowia Matki Polki · Lodz, Poland
    • Instytut "Pomnik - Centrum Zdrowia Dziecka" · Warsaw, Poland
    • Hospital Universitari Vall D Hebron | Nefrologia pediatrica · Barcelona, Spain
    • T.C. Saglik Bakanligi Ankara Bilkent Sehir Hastanesi Noroloji ve Ortopedi Hastanesi Noroloji Bolumu · Ankara, Turkey (Türkiye)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05196035
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 19, 2022
Start date
Mar 28, 2022
Primary completion
Apr 10, 2027 (estimated)
Completion
May 10, 2027 (estimated)
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion